PWE-153 Cost Effectiveness of Rifaximin-A in the Reduction of Recurrence of Overt Hepatic Encephalopathy

Gut - United Kingdom
doi 10.1136/gutjnl-2014-307263.413
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2018English

Economic Impact of the Use of Rifaximin 550 Mg Twice Daily for the Treatment of Overt Hepatic Encephalopathy in Italy

Hepatic Medicine: Evidence and Research
Hepatology
2017English

Prevention of Hepatic Encephalopathy Recurrence

Clinical Liver Disease
Hepatology
2015English

Safety, Efficacy, and Patient Acceptability of Rifaximin for Hepatic Encephalopathy

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2014English

L-Ornithine L-Aspartate in Bouts of Overt Hepatic Encephalopathy

Hepatology
MedicineHepatology
2017English

Neuroprotective Effect of Nortriptyline in Overt Hepatic Encephalopathy Through Attenuation of Mitochondrial Dysfunction

ASN Neuro
NeuroscienceNeurology
2018English

Grading the Range of Hepatic Encephalopathy From Overt to Covert: Animals to the Rescue!

Hepatology
MedicineHepatology
2017English

Rifaximin for the Prevention and Treatment of Hepatic Encephalopathy: A Systematic Review With Meta-Analyses of Randomised Controlled Trials

Journal of Clinical and Experimental Hepatology
Hepatology
2017English

Terminating an Episode of Overt Hepatic Encephalopathy- Lornithine L-Aspartate May Have Some Role

Hepatology
MedicineHepatology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy